| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/28/2002 | WO2002016620A2 Modulation of stem cell differentiation |
| 02/28/2002 | WO2002016615A2 Crystal structure of dimethylarginine dimethylaminohydrolase and arginine deiminase |
| 02/28/2002 | WO2002016597A2 Lipid metabolism enzymes |
| 02/28/2002 | WO2002016585A2 Imidazoline receptor homologs |
| 02/28/2002 | WO2002016584A2 Process for the preparation of neutrophil inhibitory factor |
| 02/28/2002 | WO2002016567A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/28/2002 | WO2002016426A2 Coaster, a human coactivator of steroid receptors |
| 02/28/2002 | WO2002016419A2 Progression suppressed gene 13 (psgen 13) and uses thereof |
| 02/28/2002 | WO2002016416A2 Diagnosis and treatment of cardiovascular conditions |
| 02/28/2002 | WO2002016405A1 S-nitrosothiols and their use as medicaments for cardiovascular diseases |
| 02/28/2002 | WO2002016394A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds |
| 02/28/2002 | WO2002016393A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016392A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016381A2 Composition and method for inhibiting platelet aggregation |
| 02/28/2002 | WO2002016370A1 1h-imidazopyridine derivatives |
| 02/28/2002 | WO2002016359A1 Fused pyrazole derivatives being protein kinase inhibitors |
| 02/28/2002 | WO2002016352A1 Quinazoline derivatives |
| 02/28/2002 | WO2002016351A1 Quinazoline derivatives as kinase inhibitors |
| 02/28/2002 | WO2002016340A1 Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same |
| 02/28/2002 | WO2002016339A1 Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same |
| 02/28/2002 | WO2002016338A1 Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same |
| 02/28/2002 | WO2002016332A1 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| 02/28/2002 | WO2002016331A1 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| 02/28/2002 | WO2002016326A1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases |
| 02/28/2002 | WO2002016325A1 Uses of thaliporphine or its derivatives in treatment of cardiac diseases and preparation of same |
| 02/28/2002 | WO2002016319A1 Novel thiourea compounds and the pharmaceutical compositions containing the same |
| 02/28/2002 | WO2002016316A1 10-ARYL-11-HBENZO [b]FLUORENE DERIVATIVES AND ANALOGS FOR MEDICINAL USE |
| 02/28/2002 | WO2002016315A1 Aza-amino acid derivatives (factor xa-inhibitors 15) |
| 02/28/2002 | WO2002016311A1 Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 02/28/2002 | WO2002015941A1 A method for reducing stress-induced overproduction of neuropeptide y in an individual |
| 02/28/2002 | WO2002015935A1 Fibrinogen lowering agents |
| 02/28/2002 | WO2002015933A2 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser |
| 02/28/2002 | WO2002015923A1 Orally administered peptides to ameliorate atherosclerosis |
| 02/28/2002 | WO2002015920A2 Treatment of hyperproliferative diseases |
| 02/28/2002 | WO2002015919A2 Saratin for inhibiting platelet adhesion to collagen |
| 02/28/2002 | WO2002015917A1 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 02/28/2002 | WO2002015893A2 Treatment of wounds |
| 02/28/2002 | WO2002015892A2 Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors |
| 02/28/2002 | WO2002015891A2 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors |
| 02/28/2002 | WO2002015886A2 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015885A2 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015879A1 A method of treating a systemic disease |
| 02/28/2002 | WO2002015878A1 Aqueous suspension preparations |
| 02/28/2002 | WO2002015845A2 Anti-hypercholesterolemic drug combination |
| 02/28/2002 | WO2002009667A9 Dispersions for formulating slightly or poorly soluble active ingredients |
| 02/28/2002 | WO2001087234A3 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers |
| 02/28/2002 | WO2001085779A3 Protein complexes and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001085762A3 Cancer diagnosis and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001079271A9 Albumin fusion proteins |
| 02/28/2002 | WO2001079258A9 Albumin fusion proteins |
| 02/28/2002 | WO2001077377A8 Diagnosis of diseases associated with dna replication by assessing dna methylation |
| 02/28/2002 | WO2001076530A3 Il-8 receptor antagonists |
| 02/28/2002 | WO2001073029A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 02/28/2002 | WO2001072281A3 Microspheres for active embolization |
| 02/28/2002 | WO2001070984A3 Anti-tissue factor antibodies with enhanced anticoagulant potency |
| 02/28/2002 | WO2001070224A3 Rilmenidine dressing and method for preparing same |
| 02/28/2002 | WO2001064847A3 In vitro modification of cardiac valvular xenografts |
| 02/28/2002 | WO2001064639A3 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 02/28/2002 | WO2001049309A3 Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue |
| 02/28/2002 | WO2001042216A3 Caspase inhibitors and uses thereof |
| 02/28/2002 | WO2001031029A3 Human sphingosine kinase gene |
| 02/28/2002 | WO2001017614A3 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
| 02/28/2002 | WO2001001970A3 New uses potassium channel openers, such as the treatment of epilepsy |
| 02/28/2002 | WO2000073307A8 Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors |
| 02/28/2002 | WO2000067746A8 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 02/28/2002 | WO2000040569A9 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 02/28/2002 | US20020026236 Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia |
| 02/28/2002 | US20020026056 Substituted imidazoles having cytokine inhibitory activity |
| 02/28/2002 | US20020026051 Calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstriction activity |
| 02/28/2002 | US20020026050 Thrombin receptor antagonists |
| 02/28/2002 | US20020026040 And isolated nucleic acids containing coding regions of genes encoding such proteins; for use in gene therapy treatment of cancer, autoimmune diseases, viral diseases |
| 02/28/2002 | US20020026034 3-aminoethyl-n-amidino-2,5-dihydropyrrole derivatives having arginine mimetic properties |
| 02/28/2002 | US20020025985 Apoptosis inhibitor |
| 02/28/2002 | US20020025983 Anticoagulant mixture; cardiovascular disordrs; premenstrual disorders; bone disorders |
| 02/28/2002 | US20020025981 Synergistic mixture of amlodipine and statins |
| 02/28/2002 | US20020025970 Materials and methods for the treatment of gastroesophageal reflux disease |
| 02/28/2002 | US20020025966 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments |
| 02/28/2002 | US20020025961 Platelet ADP receptor inhibitors |
| 02/28/2002 | US20020025957 Anticoagulants, cardiovascular disorders |
| 02/28/2002 | US20020025941 Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal |
| 02/28/2002 | US20020025935 Antiinflammatory agents; autoimmune diseases; central nervous system disorders |
| 02/28/2002 | US20020025934 Renin inhibitor |
| 02/28/2002 | US20020025577 Eukaryotic gene expression cassette and uses thereof |
| 02/28/2002 | US20020025536 Methods and reagents for isolating biologically active antibodies |
| 02/28/2002 | US20020025350 Dietary supplements |
| 02/28/2002 | US20020025348 Treatment for inflammatory bowel disease (IBD) and related conditions |
| 02/28/2002 | US20020025321 Composition for the prevention and/or treatment of atherosclerosis |
| 02/28/2002 | US20020023877 Methods for the production of D-chiro-inositol and the use of D-chiro-inositol obtained therefrom |
| 02/28/2002 | DE10040105A1 Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften Peptide and peptidomimetic derivatives having integrin inhibitor properties |
| 02/28/2002 | CA2456008A1 Stem cell differentiation |
| 02/28/2002 | CA2421062A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/28/2002 | CA2420482A1 Progression suppressed gene 13 (psgen 13) and uses thereof |
| 02/28/2002 | CA2420289A1 10-aryl-11-hbenzo [b]fluorene derivatives and analogs for medicinal use |
| 02/28/2002 | CA2420233A1 Method for identifying substances useful for treating inflammation using the response element to the i.kappa.b.alpha. ror receptor |
| 02/28/2002 | CA2420190A1 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2420179A1 Composition and method for inhibiting platelet aggregation |
| 02/28/2002 | CA2420071A1 Process for the preparation of neutrophil inhibitory factor |
| 02/28/2002 | CA2420024A1 Fused pyrazole derivatives being protein kinase inhibitors |
| 02/28/2002 | CA2419981A1 Coaster, a human coactivator of steroid receptors |
| 02/28/2002 | CA2419919A1 Novel imidazoline receptor homologs |